AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used Stelara in a head-to-head ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback